helpline 01494 601 400

Contingency plans for epilepsy medications in case of a no-deal Brexit

In August 2018, the Government asked pharmaceutical companies to ensure they have a minimum six week stockpile of prescription-only and pharmacy-only medicines in case of potential delays at UK borders after Brexit on 29 March 2019.

We have contacted pharmaceutical companies in the UK to find out what their individual contingency plans are. Their responses are detailed in the  table below.

Stockpiling medicines at home

Epilepsy Society's Medical Director, Professor Ley Sander has also advised people with epilepsy not to stockpile medication themselves.

"There is a lot of anxiety about supply of medication post Brexit and some people are finding ways to try to stockpile medicines themselves," he said.

"We understand people's concerns, however this has the potential to create a shortage of medication itself. It is important for everyone to stay calm and follow their normal routine when it comes to getting a repeat prescription.

"The contingency plans put in place by the Department of Health and Social Care are the most effective way to ensure that everyone has a consistent supply of their medication."

Serious shortage protocol

The Government has also confirmed that epilepsy medicines will be exempt from its serious shortage protocol. This will give pharmacists power to dispense alternative drugs if those prescribed by GPs are in short supply at any time, including during the possibility of a 'no-deal Brexit' scenario after Britain leaves the EU.

If there is a shortage of a particular epilepsy medication, clinicians would advise the most appropriate course of action. Where necessary, the Department of Health and Social Care would seek to access the medication from an alternative source.

Brexit contingency plans for epilepsy medications from pharmaceutical companies

Acetazolmide tablets

Company: Crescent Pharma

Dosage: 250mg

Contingency Plan: No concerns. This particular drug is manufactured wholly within the UK and therefore, they do not anticipate any concerns in regard of the manufacture and supply of this drug.

Briviact (briviracetam) oral solution

Company: UCB

Dosage: 10mg/ml 

Contingency Plan: "Ensuring patients avoid any disruption to the supply of their medicines is a primary priority for UCB, and as a precautionary measure UCB is increasing stockholding of our core medicines in the UK to cover a 2-month supply period for all products, and a 3-month supply period for many of our medicines to mitigate any potential disruption in a “hard” / “no deal” Brexit scenario.

For UCBs’ AEDs there will be a 2 month supply cover for Keppra (Levetiracetam) in the UK, and a 3-month supply period for Briviact (Brivaracetam), Vimpat (Lacosamide) and Nootropil (Piracetam).

The Medicines Supply Contingency Planning Department for the Department of Health has requested all UK pharma companies to increase their stock holding by 6 weeks (on top of their existing safety stock) to cover the impact of a ‘hard’ Brexit, which UCB has complied with. In addition, the UK Government announced that in the event of a “hard” / “no deal” Brexit many important elements and processes relating to the supply chain for medicines coming to the UK from the EU will remain the same as they are today after March 29th 2019, and that the Government would give pharmaceutical manufacturers at least 2 years notice before any proposed changes to this would be considered.

Because avoiding disruption to patients is a key priority for UCB, we continue to actively and routinely engage UK Government to encourage the development of policies that will avoid disruption to UK patients receiving their medicines."

Carbagen (carbamazepine) tablets

Company: Mylan

Dosage: 100mg, 200mg and 400mg

Contingency Plan: "Our official position regarding the events you have stated is being determined as we speak. Once we have an official statement this will be communicated".

Updated information: Mylan have informed the DHSC that the following preparations of Carbagen (carbamazepine) will be unavailable until mid-late 2019. The affected products are listed below:

  • Carbagen 200mg and 400mg Immediate Release Tablets – unavailable until mid-2019
  • Carbagen 200mg  and 400mg Modified Release Tablets – unavailable until late 2019

Patients currently prescribed Carbagen tablets by brand will therefore need to be switched to an alternative brand of carbamazepine tablets during this time.

Carbagen prolonged release (carbamazepine) tablets

Company: Mylan

Dosage: 200mg and 400mg

Contingency Plan: "Our official position regarding the events you have stated is being determined as we speak. Once we have an official statement this will be communicated".

 

Clonazepam oral solution

Company: Rosemont Pharma

Dosage: 0.5mg/ml and 2mg/5ml

Contingency Plan: "We do not anticipate any problem with the supplies."

Clonazepam oral solution

Company: Thame Laboratories

Dosage: 0.5mg/5ml and 2mg/5ml

Contingency Plan: "We do not anticipate any supply issues with Clonazepam 0.5mg/5ml and 2mg/5ml Oral Solution with either outcome of Brexit."

Convulex (valproic acid) tablets

Company: Gerot Lannach (Pfizer UK is the distribution partner)

Dosage: 150mg 

Contingency Plan: "At this moment I see good coverage for the market . And no issue with supplies of Convulex. I am coordinating between the market and the supplier and will keep you updated".

Desitrend (levetiracetam) granules

Company: Desitin Pharma

Dosage: 250mg, 500mg and 1000mg

Contingency Plan: Desitin Pharma has in place plans to manufacture and hold in the UK, by the beginning of March 2019, 6 months' safety stock of anti-epileptic medication.

Desitrend concentrate solution for infusion

Company: Desitin Pharma

Dosage: 100mg/ml

Contingency Plan: Desitin Pharma has in place plans to manufacture and hold in the UK, by the beginning of March 2019, 6 months' safety stock of anti-epileptic medication.
 

 

Diacomit (stiripentol) capsules

Company: Biocodex

Dosage: 250mg and 500mg

Contingency Plan: Biocodex have said there won’t be any problem with the supplies of Diacomit.

Diacomit (stiripentol) sachets/powder

Company: Biocodex

Dosage: 250mg and 500mg

Contingency Plan: Biocodex have said there won’t be any problem with the supplies of Diacomit.

Epanutin (phenytoin) in oral suspension

Company: Pfizer

Dosage: 30mg/5ml

Contingency Plan: "In order to minimize any potential patient impact we have undertaken work to ensure we can continue to supply in the EU and the UK covering all Brexit scenarios.  We have carried out detailed assessments of the supply of all our medicines with the focus on ensuring we will continue to have them available for our patients.  Due to the long lead times we have in our supply chains, and in the interests of all patients across Europe, we are asking the EU and the UK to reach appropriate arrangements for alignment and cooperation for medicines regulation and supply, and to support these alongside other elements to foster longer-term regulatory continuity between the EU and UK".

Epanutin (phenytoin) chewable infatabs

Company: Pfizer

Dosage: 50mg

Contingency Plan: "In order to minimize any potential patient impact we have undertaken work to ensure we can continue to supply in the EU and the UK covering all Brexit scenarios.  We have carried out detailed assessments of the supply of all our medicines with the focus on ensuring we will continue to have them available for our patients.  Due to the long lead times we have in our supply chains, and in the interests of all patients across Europe, we are asking the EU and the UK to reach appropriate arrangements for alignment and cooperation for medicines regulation and supply, and to support these alongside other elements to foster longer-term regulatory continuity between the EU and UK".

Epilim (sodium valproate) liquid

Company: Sanofi

Dosage: 200ml/5ml

Contingency Plan: "Sanofi welcomes the UK Government’s guidance in the event of no deal in the Brexit negotiations published on 23 August. Sanofi is confident that its existing contingency plans will ensure that people in the UK can access the treatments they need after the UK leaves the European Union. However, we have reviewed our stockpiling plans to meet the Government’s specific guidance to increase UK stock by 6 weeks over existing arrangements".

Epilim (sodium valproate) syrup

Company: Sanofi

Dosage: 200ml/5ml

Contingency Plan: "Sanofi welcomes the UK Government’s guidance in the event of no deal in the Brexit negotiations published on 23 August. Sanofi is confident that its existing contingency plans will ensure that people in the UK can access the treatments they need after the UK leaves the European Union. However, we have reviewed our stockpiling plans to meet the Government’s specific guidance to increase UK stock by 6 weeks over existing arrangements".

Epilim (sodium valproate) gastro and crushable tablets

Company: Sanofi

Dosage: 200mg and 500mg

Contingency Plan: "Sanofi welcomes the UK Government’s guidance in the event of no deal in the Brexit negotiations published on 23 August. Sanofi is confident that its existing contingency plans will ensure that people in the UK can access the treatments they need after the UK leaves the European Union. However, we have reviewed our stockpiling plans to meet the Government’s specific guidance to increase UK stock by 6 weeks over existing arrangements".

Epilim Chrono (sodium valproate) controlled release tablets

Company: Sanofi

Dosage: 100mg

Contingency Plan: "Sanofi welcomes the UK Government’s guidance in the event of no deal in the Brexit negotiations published on 23 August. Sanofi is confident that its existing contingency plans will ensure that people in the UK can access the treatments they need after the UK leaves the European Union. However, we have reviewed our stockpiling plans to meet the Government’s specific guidance to increase UK stock by 6 weeks over existing arrangements".

Epilim Chronosphere (sodium valproate) sachets

Company: Sanofi

Dosage: 50mg, 100mg, 250mg, 500mg, 700mg and 1000mg.

Contingency Plan: "Sanofi welcomes the UK Government’s guidance in the event of no deal in the Brexit negotiations published on 23 August. Sanofi is confident that its existing contingency plans will ensure that people in the UK can access the treatments they need after the UK leaves the European Union. However, we have reviewed our stockpiling plans to meet the Government’s specific guidance to increase UK stock by 6 weeks over existing arrangements".

Episenta (sodium valproate) capsules

Company: Desitin Pharma

Dosage: 150mg and 300mg

Contingency Plan: "Desitin Pharma has in place plans to manufacture and hold in the UK 6 month's safety stock of anti-epileptic medication by the beginning of March 2019."

 

 

 

Episenta (sodium valproate) granules

Company: Desitin Pharma

Dosage: 500mg and 1000mg

Contingency Plan: "Desitin Pharma has in place plans to manufacture and hold in the UK 6 month's safety stock of anti-epileptic medication by the beginning of March 2019."

Episenta (sodium valproate) solution for injection or infusion

Company: Desitin Pharma

Dosage: 100mg/ml

Contingency Plan: "Desitin Pharma have in place plans to manufacture and hold in the UK 6 month's safety stock of anti-epileptic medication by the beginning of March 2019."

Epival (sodium valproate) tablets

Company: Gerot Lannach

Dosage: 300mg

Contingency Plan: "Our distribution partner, Chanelle Medical UK Ltd, have informed us that they have planned for their stock at Brexit to give six months coverage at average demand" - Lisa Kock-Stuppnik, Marketing and Sales International at Gerot Lannach.

 

Ethosuximide capsules

Company: Essential Pharma

Dosage: 250mg 

Contingency Plan: “Oral preparations of ethosuximide will remain in continued supply before and after the 29th March 2019 Brexit date; confirmed by manufacturer”.

Ethosuximide syrup

Company: Essential Pharma

Dosage: 250mg/5ml

Contingency Plan: “Oral preparations of ethosuximide will remain in continued supply before and after the 29th March 2019 Brexit date; confirmed by manufacturer”.

Frisium (clobazam) tablets

Company: Sanofi

Dosage: 200mg, 300mg and 500mg

Contingency Plan: "Sanofi welcomes the UK Government’s guidance in the event of no deal in the Brexit negotiations published on 23 August. Sanofi is confident that its existing contingency plans will ensure that people in the UK can access the treatments they need after the UK leaves the European Union. However, we have reviewed our stockpiling plans to meet the Government’s specific guidance to increase UK stock by 6 weeks over existing arrangements."

Fycompa (perampanel) tablets

Company: Eisai

Dosage: 2mg, 4mg, 6mg, 8mg, 10mg and 12mg

Contingency Plan: "The Eisai stock levels are well above the levels that were requested by the Government of six weeks."

 

 

 

Gabitril (tiagabine) tablets

Company: Teva UK

Dosage: 5mg, 10mg and 15mg

Contingency Plan: "We are in very close contact with all the relevant authorities and our aim is to ensure that medicines continue to be available without disruption after Brexit. In the meantime, we remain a strong partner to the NHS and are committed to supplying the UK and the patients who depend on us."

 

Inovelon (rufinamide) tablets

Company: Eisai

Dosage: 100mg, 200mg and 400mg

Contingency Plan: "The Eisai stock levels are well above the levels that were requested by the Government of six weeks."

Inovelon (rufinamide) oral suspension

Company: Eisai

Dosage: 40mg/ml

Contingency Plan: "The Eisai stock levels are well above the levels that were requested by the Government of six weeks."

Keppra (levetiracetam) oral solution

Company: UCB Pharma

Dosage: 100mg/ml

Contingency Plan: "Ensuring patients avoid any disruption to the supply of their medicines is a primary priority for UCB, and as a precautionary measure UCB is increasing stockholding of our core medicines in the UK to cover a 2-month supply period for all products, and a 3-month supply period for many of our medicines to mitigate any potential disruption in a “hard” / “no deal” Brexit scenario.

For UCBs’ AEDs there will be a 2 month supply cover for Keppra (Levetiracetam) in the UK, and a 3-month supply period for Briviact (Brivaracetam), Vimpat (Lacosamide) and Nootropil (Piracetam).

The Medicines Supply Contingency Planning Department for the Department of Health has requested all UK pharma companies to increase their stock holding by 6 weeks (on top of their existing safety stock) to cover the impact of a ‘hard’ Brexit, which UCB has complied with. In addition, the UK Government announced that in the event of a “hard” / “no deal” Brexit many important elements and processes relating to the supply chain for medicines coming to the UK from the EU will remain the same as they are today after March 29th 2019, and that the Government would give pharmaceutical manufacturers at least 2 years notice before any proposed changes to this would be considered.

Because avoiding disruption to patients is a key priority for UCB, we continue to actively and routinely engage UK Government to encourage the development of policies that will avoid disruption to UK patients receiving their medicines."

Keppra (levetiracetam) tablets

Company: UCB

Dosage: 250mg, 500mg, 750mg and 1000mg

Contingency Plan: "Ensuring patients avoid any disruption to the supply of their medicines is a primary priority for UCB, and as a precautionary measure UCB is increasing stockholding of our core medicines in the UK to cover a 2-month supply period for all products, and a 3-month supply period for many of our medicines to mitigate any potential disruption in a “hard” / “no deal” Brexit scenario.

For UCBs’ AEDs there will be a 2 month supply cover for Keppra (Levetiracetam) in the UK, and a 3-month supply period for Briviact (Brivaracetam), Vimpat (Lacosamide) and Nootropil (Piracetam).

The Medicines Supply Contingency Planning Department for the Department of Health has requested all UK pharma companies to increase their stock holding by 6 weeks (on top of their existing safety stock) to cover the impact of a ‘hard’ Brexit, which UCB has complied with. In addition, the UK Government announced that in the event of a “hard” / “no deal” Brexit many important elements and processes relating to the supply chain for medicines coming to the UK from the EU will remain the same as they are today after March 29th 2019, and that the Government would give pharmaceutical manufacturers at least 2 years notice before any proposed changes to this would be considered.

Because avoiding disruption to patients is a key priority for UCB, we continue to actively and routinely engage UK Government to encourage the development of policies that will avoid disruption to UK patients receiving their medicines."

Lamictal (lamotrigine) dispersible tablets

Company: Glaxo-Smith Kline (GSK)

Dosage: 2mg, 5mg, 25mg and 100mg

Contingency Plan: "Until there is formal agreement, we will continue to implement our contingency plans for all scenarios, including no deal."

Lamictal (lamotrigine) tablets

Company: Glaxo-Smith Kline (GSK)

Dosage: 25mg, 50mg, 100mg and 200mg

Contingency Plan: "Until there is formal agreement, we will continue to implement our contingency plans for all scenarios, including no deal."

Lyrica (pregabalin) capsules

Company: Pfizer

Dosage: 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg

Contingency Plan: "In order to minimize any potential patient impact we have undertaken work to ensure we can continue to supply in the EU and the UK covering all Brexit scenarios.  We have carried out detailed assessments of the supply of all our medicines with the focus on ensuring we will continue to have them available for our patients.  Due to the long lead times we have in our supply chains, and in the interests of all patients across Europe, we are asking the EU and the UK to reach appropriate arrangements for alignment and cooperation for medicines regulation and supply, and to support these alongside other elements to foster longer-term regulatory continuity between the EU and UK."

Lyrica (pregabalin) oral solution

Company: Pfzier

Dosage: 20mg/ml

Contingency Plan: "In order to minimize any potential patient impact we have undertaken work to ensure we can continue to supply in the EU and the UK covering all Brexit scenarios.  We have carried out detailed assessments of the supply of all our medicines with the focus on ensuring we will continue to have them available for our patients.  Due to the long lead times we have in our supply chains, and in the interests of all patients across Europe, we are asking the EU and the UK to reach appropriate arrangements for alignment and cooperation for medicines regulation and supply, and to support these alongside other elements to foster longer-term regulatory continuity between the EU and UK."

Neurontin (gabapentin) tablets

Company: Pfizer

Dosage: 600mg and 800mg

Contingency Plan: "In order to minimize any potential patient impact we have undertaken work to ensure we can continue to supply in the EU and the UK covering all Brexit scenarios.  We have carried out detailed assessments of the supply of all our medicines with the focus on ensuring we will continue to have them available for our patients.  Due to the long lead times we have in our supply chains, and in the interests of all patients across Europe, we are asking the EU and the UK to reach appropriate arrangements for alignment and cooperation for medicines regulation and supply, and to support these alongside other elements to foster longer-term regulatory continuity between the EU and UK."

Neurontin (gabapentin) capsules

Company: Pfizer

Dosage: 100mg, 300mg and 400mg

Contingency Plan: "In order to minimize any potential patient impact we have undertaken work to ensure we can continue to supply in the EU and the UK covering all Brexit scenarios.  We have carried out detailed assessments of the supply of all our medicines with the focus on ensuring we will continue to have them available for our patients.  Due to the long lead times we have in our supply chains, and in the interests of all patients across Europe, we are asking the EU and the UK to reach appropriate arrangements for alignment and cooperation for medicines regulation and supply, and to support these alongside other elements to foster longer-term regulatory continuity between the EU and UK."

Nootropil (piracetam) tablets

Company: UCB Pharma

Dosage: 800mg and 1200mg

Contingency Plan: "Ensuring patients avoid any disruption to the supply of their medicines is a primary priority for UCB, and as a precautionary measure UCB is increasing stockholding of our core medicines in the UK to cover a 2-month supply period for all products, and a 3-month supply period for many of our medicines to mitigate any potential disruption in a “hard” / “no deal” Brexit scenario.

For UCBs’ AEDs there will be a 2 month supply cover for Keppra (Levetiracetam) in the UK, and a 3-month supply period for Briviact (Brivaracetam), Vimpat (Lacosamide) and Nootropil (Piracetam).

The Medicines Supply Contingency Planning Department for the Department of Health has requested all UK pharma companies to increase their stock holding by 6 weeks (on top of their existing safety stock) to cover the impact of a ‘hard’ Brexit, which UCB has complied with. In addition, the UK Government announced that in the event of a “hard” / “no deal” Brexit many important elements and processes relating to the supply chain for medicines coming to the UK from the EU will remain the same as they are today after March 29th 2019, and that the Government would give pharmaceutical manufacturers at least 2 years notice before any proposed changes to this would be considered.

Because avoiding disruption to patients is a key priority for UCB, we continue to actively and routinely engage UK Government to encourage the development of policies that will avoid disruption to UK patients receiving their medicines."

Nootropil (piracetam) solution

Company: UCB Pharma

Dosage: 333.3mg/ml

Contingency Plan: "Ensuring patients avoid any disruption to the supply of their medicines is a primary priority for UCB, and as a precautionary measure UCB is increasing stockholding of our core medicines in the UK to cover a 2-month supply period for all products, and a 3-month supply period for many of our medicines to mitigate any potential disruption in a “hard” / “no deal” Brexit scenario.

For UCBs’ AEDs there will be a 2 month supply cover for Keppra (Levetiracetam) in the UK, and a 3-month supply period for Briviact (Brivaracetam), Vimpat (Lacosamide) and Nootropil (Piracetam).

The Medicines Supply Contingency Planning Department for the Department of Health has requested all UK pharma companies to increase their stock holding by 6 weeks (on top of their existing safety stock) to cover the impact of a ‘hard’ Brexit, which UCB has complied with. In addition, the UK Government announced that in the event of a “hard” / “no deal” Brexit many important elements and processes relating to the supply chain for medicines coming to the UK from the EU will remain the same as they are today after March 29th 2019, and that the Government would give pharmaceutical manufacturers at least 2 years notice before any proposed changes to this would be considered.

Because avoiding disruption to patients is a key priority for UCB, we continue to actively and routinely engage UK Government to encourage the development of policies that will avoid disruption to UK patients receiving their medicines."

Perizam (clobazam) tablets

Company: Auden McKenzie

Dosage: 10mg

Contingency Plan: Awaiting update

Phenobarbital tablets

Company: Teva UK

Dosage: 15mg, 30mg and 60mg

Contingency Plan: "We are in very close contact with all the relevant authorities and our aim is to ensure that medicines continue to be available without disruption after Brexit. In the meantime, we remain a strong partner to the NHS and are committed to supplying the UK and the patients who depend on us."
 

 

Phenobarbital Elixir

Company: Thornton & Ross Limited

Dosage: 15mg/5ml

Contingency Plan: "We do not currently anticipate problems as many of our products are made on site for the UK market and we currently have adequate stocks of raw materials for production."

Phenytoin sodium capsules

Company: Flynn Pharma

Dosage: 25mg, 50mg, 100mg and 300mg

Contingency Plan: "We hold and have good access to safety stocks of all strengths of the product in the UK and will continue to do so, increasing those stocks ahead of ‘Brexit’ if required. Demand is monitored on a daily basis."

Primidone tablets

Company: Teva UK

Dosage: 50mg and 250mg

Contingency Plan: "We are in very close contact with all the relevant authorities and our aim is to ensure that medicines continue to be available without disruption after Brexit. In the meantime, we remain a strong partner to the NHS and are committed to supplying the UK and the patients who depend on us".

 

Sabril (vigabatrin) tablets

Company: Sanofi

Dosage: 500mg

Contingency Plan: "Sanofi welcomes the UK Government’s guidance in the event of no deal in the Brexit negotiations published on 23 August. Sanofi is confident that its existing contingency plans will ensure that people in the UK can access the treatments they need after the UK leaves the European Union. However, we have reviewed our stockpiling plans to meet the Government’s specific guidance to increase UK stock by 6 weeks over existing arrangements".

Sabril (vigabatrin) powder for oral solution

Company: Sanofi

Dosage: 500mg

Contingency Plan: "Sanofi welcomes the UK Government’s guidance in the event of no deal in the Brexit negotiations published on 23 August. Sanofi is confident that its existing contingency plans will ensure that people in the UK can access the treatments they need after the UK leaves the European Union. However, we have reviewed our stockpiling plans to meet the Government’s specific guidance to increase UK stock by 6 weeks over existing arrangements".

Tapclob (clobazam) oral suspension

Company: Martindale Pharma

Dosage: 5mg/5ml, 150ml and 250ml bottles 

Contingency Plan: "I can confirm that all lines of Tapclob, 5mg/5ml 150ml and 250ml bottles and 10mg/5ml 150ml and 250ml bottles, are UK sourced lines that are manufactured and packed in the UK and therefore, we are anticipating minimal impact on the supply of these products. However, we are working closely with our suppliers of materials and components to ensure that we have safety stocks in place ahead of the March 2019 deadline".

Tapclob (clobazam) oral suspension

Company: Martindale Pharma

Dosage: 10mg/5ml, 150ml and 250ml bottles

Contingency Plan: "I can confirm that all lines of Tapclob, 5mg/5ml 150ml and 250ml bottles and 10mg/5ml 150ml and 250ml bottles, are UK sourced lines that are manufactured and packed in the UK and therefore, we are anticipating minimal impact on the supply of these products. However, we are working closely with our suppliers of materials and components to ensure that we have safety stocks in place ahead of the March 2019 deadline".

Tegretol (carbamazepine) liquid

Company: Novartis UK

Dosage: 100mg/5ml

Contingency Plan: "Will meet Government’s specific guidance to increase UK stock by 6 weeks over existing arrangements."

 

Tegretol (carbamazepine) prolonged release tablets

Company: Novartis UK

Dosage: 200mg

Contingency Plan: "Will meet Government’s specific guidance to increase UK stock by 6 weeks over existing arrangements."

Updated information: Due to some preparations of Carbagen (carbamazepine) manufactured by Mylan being unavailable until mid-late 2019, Novartis, which is the alternative brand of carbamazepine tablets, have confirmed that they are able to support additional demand during this time for all affected strengths and formulations.

Topamax (topiramate) tablets

Company: Janssen Cilag

Dosage: 25mg, 50mg, 100mg and 200mg

Contingency Plan: "Will meet Government’s specific guidance to increase UK stock by 6 weeks over existing arrangements."

 

Topamax (topiramate) sprinkle capsules

Company: Janssen Cilag

Dosage: 15mg, 25mg and 50mg

Contingency Plan: "Will meet Government’s specific guidance to increase UK stock by 6 weeks over existing arrangements."

Trileptal (oxcarbazepine) tablets

Company: Novartis UK

Dosage: 150mg, 300mg and 600mg

Contingency Plan: "Will meet Government’s specific guidance to increase UK stock by 6 weeks over existing arrangements."

Trileptal (oxcarbazepine) oral suspension

Company: Novartis UK

Dosage: 60mg/ml

Contingency Plan: "Will meet Government’s specific guidance to increase UK stock by 6 weeks over existing arrangements."

Vimpat (lacosamide) syrup

Company: UCB Pharma

Dosage: 10mg/ml

Contingency Plan: "Ensuring patients avoid any disruption to the supply of their medicines is a primary priority for UCB, and as a precautionary measure UCB is increasing stockholding of our core medicines in the UK to cover a 2-month supply period for all products, and a 3-month supply period for many of our medicines to mitigate any potential disruption in a “hard” / “no deal” Brexit scenario.

For UCBs’ AEDs there will be a 2 month supply cover for Keppra (Levetiracetam) in the UK, and a 3-month supply period for Briviact (Brivaracetam), Vimpat (Lacosamide) and Nootropil (Piracetam).

The Medicines Supply Contingency Planning Department for the Department of Health has requested all UK pharma companies to increase their stock holding by 6 weeks (on top of their existing safety stock) to cover the impact of a ‘hard’ Brexit, which UCB has complied with. In addition, the UK Government announced that in the event of a “hard” / “no deal” Brexit many important elements and processes relating to the supply chain for medicines coming to the UK from the EU will remain the same as they are today after March 29th 2019, and that the Government would give pharmaceutical manufacturers at least 2 years notice before any proposed changes to this would be considered.

Because avoiding disruption to patients is a key priority for UCB, we continue to actively and routinely engage UK Government to encourage the development of policies that will avoid disruption to UK patients receiving their medicines."

Vimpat (lacosamide) tablets

Company: UCB Pharma

Dosage: 50mg, 100mg, 150mg and 200mg

Contingency Plan: "Ensuring patients avoid any disruption to the supply of their medicines is a primary priority for UCB, and as a precautionary measure UCB is increasing stockholding of our core medicines in the UK to cover a 2-month supply period for all products, and a 3-month supply period for many of our medicines to mitigate any potential disruption in a “hard” / “no deal” Brexit scenario.

For UCBs’ AEDs there will be a 2 month supply cover for Keppra (Levetiracetam) in the UK, and a 3-month supply period for Briviact (Brivaracetam), Vimpat (Lacosamide) and Nootropil (Piracetam).

The Medicines Supply Contingency Planning Department for the Department of Health has requested all UK pharma companies to increase their stock holding by 6 weeks (on top of their existing safety stock) to cover the impact of a ‘hard’ Brexit, which UCB has complied with. In addition, the UK Government announced that in the event of a “hard” / “no deal” Brexit many important elements and processes relating to the supply chain for medicines coming to the UK from the EU will remain the same as they are today after March 29th 2019, and that the Government would give pharmaceutical manufacturers at least 2 years notice before any proposed changes to this would be considered.

Because avoiding disruption to patients is a key priority for UCB, we continue to actively and routinely engage UK Government to encourage the development of policies that will avoid disruption to UK patients receiving their medicines."

Zebinix (eslicarbazepine acetate) tablets

Company: Eisai

Dosage: 200mg and 800mg

Contingency Plan: "Will have a stock hold of approx. 4 months at Movianto UK (wholesalers). Wholesalers who supply UK will not be affected."

Zonegran (zonisamide) capsules

Company: Eisai

Dosage: 25mg, 50mg and 100mg

Contingency Plan: "The Eisai stock levels are well above the levels that were requested by the Government."